Urgent.News

What's breaking now, across thousands of outlets.

AI

Pathos AI, which uses AI to develop oncology drugs, raised a $237M Series E at a $3B post-money valuation, up from $1.6B after its $365M Series D in May 2025 (Katherine Davis/Axios)

Precision oncology biotech Pathos AI said Friday it raised a $237 million Series E round at a $3 billion post-money valuation.

We haven't written up this one. Techmeme has the full story — the link below goes straight to it.

Read the original at axios.com →

More in AI

Coreline Soft Expands Lung Cancer Screening AI Beyond Detection to Integrated Screening and Follow-Up Management

Artificial intelligence in lung cancer screening is moving beyond the early detection of pulmonary nodules toward integrated screening operations, longitudinal imaging analysis and patient follow-up…

  • Coreline Soft develops AI platform for integrated lung cancer screening and follow-up management.
  • AVIEW HUB connects imaging data across institutions to streamline screening workflows.

More from Friday 23 October →